Neurocrine Biosciences And Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating That One-Time Treatment With An Investigational Gene Therapy Showed Sustained Improvement In Motor Function In Patients With Parkinson’s Disease

Editas Medicine Announces U.S. Patent And Trademark Office Grants The Broad Institute Priority Benefit In CRISPR Interference

Casma Therapeutics Announces $50 Million Series B Financing

Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™

Sage Therapeutics’ FutureCast to Provide Update on Pipeline Progression and Additional Insights into Potential of Brain Health Franchises